From the Desk of the CEO

Semaglutide, a GLP-1 receptor agonist, has lowered the risk of CV events for untold patients with T2D. But does the drug offer the same protective effects to the growing number of people without diabetes who now take the drug for weight loss? New research says “yes.”

Sonya Collin

Over half of survey participants were open to using pharmacies for testing and treatment of influenza and group A streptococcal pharyngitis infections, according to study results published in the January/February 2023 issue of JAPhA. They were also willing to pay $25 or more for out-of-pocket testing costs.

Clarissa Chan, PharmD

More than 42% of Americans have obesity. Given that obesity raises risk for numerous chronic illnesses and cancers, this subset of the population likely receives a substantial proportion of the medications prescribed in the United States. But they might not be getting the right dose.

Sonya Collins

In late October 2019, FDA approved elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta—Vertex Pharmaceuticals), the first triple-combination therapy to treat patients ages 12 years and older with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is estimated to represent 90% of the cystic fibrosis (CF) population.

Cara Aldridge Young

When discussing cholesterol, most clinicians cite HDL and LDL as the primary cholesterol factors influencing atherosclerotic risk. Lipoprotein(a), also known as Lp(a), is another, less commonly discussed piece of the puzzle in determining risk for atherosclerotic CVD (ASCVD).

Olivia C. Welter, PharmD